Eagle Net Receivables vs Total Liab Analysis

EGRX Stock

USD 4.76 0.01 0.21%

Eagle Pharmaceuticals financial indicator trend analysis is much more than just examining Eagle Pharmaceuticals latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Eagle Pharmaceuticals is a good investment. Please check the relationship between Eagle Pharmaceuticals Net Receivables and its Total Liab accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eagle Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Eagle Stock please use our How to Invest in Eagle Pharmaceuticals guide.

Net Receivables vs Total Liab

Net Receivables vs Total Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Eagle Pharmaceuticals Net Receivables account and Total Liab. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Eagle Pharmaceuticals' Net Receivables and Total Liab is 0.91. Overlapping area represents the amount of variation of Net Receivables that can explain the historical movement of Total Liab in the same time period over historical financial statements of Eagle Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Eagle Pharmaceuticals' Net Receivables and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Receivables of Eagle Pharmaceuticals are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Net Receivables i.e., Eagle Pharmaceuticals' Net Receivables and Total Liab go up and down completely randomly.

Correlation Coefficient

0.91

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Net Receivables

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Most indicators from Eagle Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Eagle Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eagle Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Eagle Stock please use our How to Invest in Eagle Pharmaceuticals guide.At this time, Eagle Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 31.1 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 0.25 in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	1.6M	4.0M	4.7M	4.9M
Depreciation And Amortization	3.8M	12.0M	13.8M	14.5M

Interest Expense Depreciation And Amortization

Eagle Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross
Total Assets		0.65	0.82	0.92	0.89	0.39	0.79	-0.02	0.94	0.93	0.64	0.96	0.86	0.93	0.91	0.63	0.98	0.8	0.66	-0.24	0.93	0.86	0.77	0.1	0.96	0.9
Short Long Term Debt Total	0.65		0.58	0.53	0.7	0.3	0.44	-0.11	0.48	0.59	0.41	0.6	0.51	0.55	0.46	0.43	0.66	0.75	0.55	0.26	0.68	0.55	0.57	0.52	0.59	0.52
Other Current Liab	0.82	0.58		0.94	0.56	0.06	0.45	0.42	0.63	0.83	0.15	0.92	0.94	0.88	0.69	0.14	0.74	0.46	0.39	-0.18	0.84	0.95	0.46	0.09	0.92	0.81
Total Current Liabilities	0.92	0.53	0.94		0.7	0.13	0.66	0.27	0.82	0.93	0.36	0.96	0.96	0.94	0.88	0.34	0.84	0.59	0.43	-0.2	0.85	0.98	0.61	-0.03	0.97	0.93
Total Stockholder Equity	0.89	0.7	0.56	0.7		0.48	0.87	-0.32	0.89	0.79	0.79	0.77	0.62	0.77	0.8	0.77	0.9	0.92	0.73	-0.25	0.78	0.63	0.86	0.24	0.76	0.76
Property Plant And Equipment Net	0.39	0.3	0.06	0.13	0.48		0.19	-0.56	0.33	0.34	0.71	0.22	-0.05	0.14	0.31	0.69	0.45	0.48	0.74	-0.44	0.37	0.0	0.58	0.5	0.24	0.4
Current Deferred Revenue	0.79	0.44	0.45	0.66	0.87	0.19		-0.12	0.91	0.69	0.61	0.72	0.62	0.73	0.82	0.58	0.78	0.69	0.43	-0.17	0.65	0.58	0.8	-0.21	0.7	0.66
Net Debt	-0.02	-0.11	0.42	0.27	-0.32	-0.56	-0.12		-0.07	0.09	-0.74	0.24	0.41	0.21	0.04	-0.74	-0.07	-0.46	-0.53	0.17	0.17	0.33	-0.26	-0.54	0.25	0.04
Retained Earnings	0.94	0.48	0.63	0.82	0.89	0.33	0.91	-0.07		0.82	0.69	0.87	0.78	0.87	0.93	0.67	0.93	0.75	0.53	-0.22	0.84	0.74	0.76	-0.15	0.87	0.81
Accounts Payable	0.93	0.59	0.83	0.93	0.79	0.34	0.69	0.09	0.82		0.46	0.93	0.81	0.92	0.86	0.45	0.88	0.71	0.58	-0.23	0.81	0.86	0.75	0.13	0.92	0.95
Cash	0.64	0.41	0.15	0.36	0.79	0.71	0.61	-0.74	0.69	0.46		0.4	0.23	0.4	0.61	0.99	0.68	0.81	0.76	-0.3	0.49	0.27	0.68	0.32	0.42	0.53
Non Current Assets Total	0.96	0.6	0.92	0.96	0.77	0.22	0.72	0.24	0.87	0.93	0.4		0.94	0.98	0.86	0.38	0.91	0.65	0.5	-0.2	0.93	0.92	0.67	-0.01	0.99	0.88
Non Currrent Assets Other	0.86	0.51	0.94	0.96	0.62	-0.05	0.62	0.41	0.78	0.81	0.23	0.94		0.93	0.8	0.22	0.77	0.49	0.27	-0.08	0.84	0.97	0.46	-0.16	0.94	0.8
Other Assets	0.93	0.55	0.88	0.94	0.77	0.14	0.73	0.21	0.87	0.92	0.4	0.98	0.93		0.83	0.38	0.87	0.64	0.46	-0.18	0.85	0.9	0.6	-0.04	0.95	0.86
Long Term Debt	0.91	0.46	0.69	0.88	0.8	0.31	0.82	0.04	0.93	0.86	0.61	0.86	0.8	0.83		0.59	0.88	0.67	0.45	-0.17	0.82	0.82	0.75	-0.17	0.9	0.91
Cash And Short Term Investments	0.63	0.43	0.14	0.34	0.77	0.69	0.58	-0.74	0.67	0.45	0.99	0.38	0.22	0.38	0.59		0.66	0.83	0.73	-0.23	0.49	0.26	0.66	0.34	0.41	0.51
Net Receivables	0.98	0.66	0.74	0.84	0.9	0.45	0.78	-0.07	0.93	0.88	0.68	0.91	0.77	0.87	0.88	0.66		0.82	0.73	-0.26	0.93	0.79	0.77	0.11	0.91	0.84
Common Stock Total Equity	0.8	0.75	0.46	0.59	0.92	0.48	0.69	-0.46	0.75	0.71	0.81	0.65	0.49	0.64	0.67	0.83	0.82		0.75	-0.1	0.69	0.54	0.76	0.44	0.64	0.65
Common Stock Shares Outstanding	0.66	0.55	0.39	0.43	0.73	0.74	0.43	-0.53	0.53	0.58	0.76	0.5	0.27	0.46	0.45	0.73	0.73	0.75		-0.53	0.58	0.36	0.66	0.61	0.5	0.54
Short Term Investments	-0.24	0.26	-0.18	-0.2	-0.25	-0.44	-0.17	0.17	-0.22	-0.23	-0.3	-0.2	-0.08	-0.18	-0.17	-0.23	-0.26	-0.1	-0.53		-0.18	-0.12	-0.27	-0.13	-0.21	-0.28
Non Current Liabilities Total	0.93	0.68	0.84	0.85	0.78	0.37	0.65	0.17	0.84	0.81	0.49	0.93	0.84	0.85	0.82	0.49	0.93	0.69	0.58	-0.18		0.81	0.69	0.07	0.94	0.78
Inventory	0.86	0.55	0.95	0.98	0.63	0.0	0.58	0.33	0.74	0.86	0.27	0.92	0.97	0.9	0.82	0.26	0.79	0.54	0.36	-0.12	0.81		0.49	-0.03	0.94	0.86
Other Current Assets	0.77	0.57	0.46	0.61	0.86	0.58	0.8	-0.26	0.76	0.75	0.68	0.67	0.46	0.6	0.75	0.66	0.77	0.76	0.66	-0.27	0.69	0.49		0.21	0.68	0.74
Other Stockholder Equity	0.1	0.52	0.09	-0.03	0.24	0.5	-0.21	-0.54	-0.15	0.13	0.32	-0.01	-0.16	-0.04	-0.17	0.34	0.11	0.44	0.61	-0.13	0.07	-0.03	0.21		-0.02	0.1
Total Liab	0.96	0.59	0.92	0.97	0.76	0.24	0.7	0.25	0.87	0.92	0.42	0.99	0.94	0.95	0.9	0.41	0.91	0.64	0.5	-0.21	0.94	0.94	0.68	-0.02		0.91
Property Plant And Equipment Gross	0.9	0.52	0.81	0.93	0.76	0.4	0.66	0.04	0.81	0.95	0.53	0.88	0.8	0.86	0.91	0.51	0.84	0.65	0.54	-0.28	0.78	0.86	0.74	0.1	0.91

Click cells to compare fundamentals

Eagle Pharmaceuticals Account Relationship Matchups

Eagle Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	254.6M	253.2M	253.7M	406.2M	467.1M	490.4M
Short Long Term Debt Total	38.6M	37.1M	25.6M	62.5M	71.8M	41.6M
Other Current Liab	2.3M	3.1M	7.0M	85.8M	98.7M	103.7M
Total Current Liabilities	38.8M	38.1M	74.4M	111.1M	127.8M	134.1M
Total Stockholder Equity	179.2M	186.0M	176.5M	233.6M	268.6M	138.0M
Property Plant And Equipment Net	2.2M	2.1M	1.6M	1.2M	1.3M	2.3M
Current Deferred Revenue	21.7M	26.1M	20.7M	25.4M	29.2M	17.3M
Net Debt	(71.2M)	(66.1M)	(72.1M)	7.1M	6.4M	6.8M
Retained Earnings	72.5M	84.5M	75.9M	111.5M	128.2M	134.6M
Accounts Payable	5.5M	6.3M	16.4M	19.0M	21.8M	22.9M
Cash	109.8M	103.2M	97.7M	55.3M	63.6M	73.0M
Non Current Assets Total	75.1M	87.1M	81.1M	217.4M	250.0M	262.5M
Non Currrent Assets Other	3.9M	5.0M	4.2M	15.7M	18.1M	19.0M
Other Assets	13.9M	32.4M	29.1M	52.9M	60.8M	63.9M
Long Term Debt	38.2M	33.6M	25.1M	56.2M	64.6M	67.9M
Cash And Short Term Investments	109.8M	103.2M	97.7M	55.3M	63.6M	75.1M
Net Receivables	48.0M	51.1M	41.1M	72.4M	83.3M	87.5M
Common Stock Shares Outstanding	14.1M	13.8M	13.1M	13.1M	15.0M	14.9M
Liabilities And Stockholders Equity	254.6M	253.2M	253.7M	406.2M	467.1M	490.4M
Non Current Liabilities Total	36.6M	29.1M	2.9M	61.5M	70.7M	74.3M
Inventory	6.6M	8.1M	21.9M	47.8M	55.0M	57.7M
Other Current Assets	15.1M	1.6M	11.9M	13.2M	15.2M	8.2M
Other Stockholder Equity	106.7M	101.5M	100.7M	123.2M	110.8M	100.8M
Total Liab	75.4M	67.2M	77.3M	172.6M	198.5M	208.4M
Property Plant And Equipment Gross	2.2M	2.1M	7.6M	7.8M	8.9M	9.4M
Total Current Assets	179.4M	166.1M	172.6M	188.8M	217.1M	137.0M
Short Term Debt	6.3M	5M	8M	25.6M	7.2M	8.5M
Property Plant Equipment	2.2M	2.1M	1.6M	1.2M	1.3M	2.3M
Net Tangible Assets	123.8M	133.4M	126.0M	70.2M	80.7M	106.8M
Retained Earnings Total Equity	72.5M	84.5M	75.9M	111.5M	128.2M	134.6M
Capital Surpluse	278.5M	305.4M	325.8M	366.3M	421.2M	282.9M
Treasury Stock	(171.9M)	(203.9M)	(225.1M)	(243.1M)	(218.8M)	(207.9M)
Intangible Assets	15.6M	12.9M	10.7M	118.3M	136.1M	142.9M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

MSFT	Microsoft
GOOG	Alphabet Inc Class C
C	Citigroup

When determining whether Eagle Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eagle Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eagle Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eagle Pharmaceuticals Stock:

How To Invest In Eagle

Details

Is Eagle Stock a good investment?

Details

What is Eagle Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eagle Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Eagle Stock please use our How to Invest in Eagle Pharmaceuticals guide.

You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.

Complementary Tools for Eagle Stock analysis

When running Eagle Pharmaceuticals' price analysis, check to measure Eagle Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eagle Pharmaceuticals is operating at the current time. Most of Eagle Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eagle Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eagle Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eagle Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios
	Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings
	Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Commodity Directory Find actively traded commodities issued by global exchanges
	AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities
	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios
	Transaction History View history of all your transactions and understand their impact on performance
	Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
	Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins

Is Eagle Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eagle Pharmaceuticals. If investors know Eagle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eagle Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.87)

Earnings Share

0.85

Revenue Per Share

19.684

Quarterly Revenue Growth

(0.13)

Return On Assets

0.0663

The market value of Eagle Pharmaceuticals is measured differently than its book value, which is the value of Eagle that is recorded on the company's balance sheet. Investors also form their own opinion of Eagle Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eagle Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eagle Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eagle Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Eagle Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eagle Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eagle Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Eagle Net Receivables vs Total Liab Analysis

Net Receivables vs Total Liab

Net Receivables vs Total Liab Correlation Analysis

Correlation Coefficient

Net Receivables

Total Liab

Eagle Pharmaceuticals fundamental ratios Correlations

Eagle Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Eagle Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Complementary Tools for Eagle Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 0.99	Cash
Total Liab	+ 0.99	Non Current Assets Total
Net Receivables	+ 0.98	Total Assets
Inventory	+ 0.98	Total Current Liabilities
Other Assets	+ 0.98	Non Current Assets Total
Total Liab	+ 0.97	Total Current Liabilities

Cash And Short Term Investments	- 0.74	Net Debt
Cash	- 0.74	Net Debt
Net Debt	- 0.56	Property Plant And Equipment Net
Other Stockholder Equity	- 0.54	Net Debt
Short Term Investments	- 0.53	Common Stock Shares Outstanding
Common Stock Shares Outstanding	- 0.53	Net Debt